Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Escalation of HSP990 in Japan/Korea

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: HSP990

First Posted Date: 2010-02-08

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01064089

Locations: 🇯🇵
Novartis Investigative Site, Kashiwa, Chiba, Japan

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: pazopanib
Drug: sunitinib

First Posted Date: 2010-02-08

Last Posted Date: 2017-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 169

Registration Number: NCT01064310

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase

Phase 4

Completed

Conditions: CML in Chronic Phase

Interventions: Drug: Nilotinib

First Posted Date: 2010-02-02

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1090

Registration Number: NCT01061177

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Phase 2

Completed

Conditions: Lymphangioleiomyomatosis

Interventions: Drug: Everolimus

First Posted Date: 2010-01-29

Last Posted Date: 2020-11-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01059318

Locations: 🇺🇸
Center for LAM Research and Clinical Care, Boston, Massachusetts, United States
🇮🇹
Novartis Investigative Site, Milan, Italy
🇺🇸
University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine,, Cincinnati, Ohio, United States

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Phase 2

Completed

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: TKI258

First Posted Date: 2010-01-28

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT01058434

Locations: 🇺🇸
University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile, Alabama, United States
🇺🇸
Duke University Medical Center Dept. of DUMC (4), Durham, North Carolina, United States
🇺🇸
St. Jude Heritage Medical Group Virginia Crosson Cancer Center, Yorba Linda, California, United States

and more 13 locations

Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.

Phase 4

Completed

Conditions: Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft

Interventions: Drug: 2
Drug: 1

First Posted Date: 2010-01-26

Last Posted Date: 2014-12-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT01056822

Locations: 🇪🇸
Novartis Investigative Site, Zaragoza, Spain

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: panobinostat/LBH589B

First Posted Date: 2010-01-25

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT01055483

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Phase 2

Completed

Conditions: Relapsing-remitting Multiple Sclerosis
RRMS

Interventions: Drug: Placebo
Drug: AIN457

First Posted Date: 2010-01-20

Last Posted Date: 2015-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT01051817

Locations: 🇺🇦
Novartis Investigative Site, Vinnitsya, Ukraine

A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine transdermal

First Posted Date: 2010-01-13

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT01047579

Locations: 🇮🇱
Novartis Investigational Site, Haifa, Israel
🇮🇱
Novartis Investigative Site, Tel Aviv, Israel

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Phase 2

Completed

Conditions: Transfusional Iron Overload

Interventions: Drug: ICL670

First Posted Date: 2010-01-07

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01044186

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇮🇹
Novartis Investigative Site, Torino, Italy
🇬🇷
Novartis investigative Site, Athens, Greece

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy